Last reviewed · How we verify
Fluoxetine - immediate treatment
At a glance
| Generic name | Fluoxetine - immediate treatment |
|---|---|
| Also known as | fluoxetine, prozac |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders (PHASE2)
- Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD (PHASE1, PHASE2)
- Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma? (PHASE4)
- Combination Therapy of Different Antidepressants With Dietary Supplements (NA)
- Bioequivalence Study of Fluoxetine in Healthy Adult Subjects Under Fasting Condition (PHASE1)
- Piloting Acute Care to Primary Care Linkage of Safety Net Patients (PHASE1)
- Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury (PHASE1)
- NMDA Antagonists in Bipolar Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxetine - immediate treatment CI brief — competitive landscape report
- Fluoxetine - immediate treatment updates RSS · CI watch RSS
- Yale University portfolio CI